Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
11 October 2012

Retirement of Chairman

The Chairman, Mr Chris Fullerton, has advised that, in order to devote time to new ventures, he will retire from the Board of Bionomics on 31 December, 2012. The Directors have agreed that, following confirmation of his Board appointment at the Company's Annual General Meeting to be held on Wednesday, 14 November, 2012, Mr Graeme Kaufman will assume the chairmanship of Bionomics.

Mr Fullerton said, "It has been a great privilege to chair a drug discovery and development company of the quality and international standing of Bionomics. The high level of commitment, professionalism and integrity displayed by Deborah Rathjen and her talented management team is second to none. Further, our Board has an enviable depth of international industry and financial experience to support our growth strategy".

Of the incoming chairman, Mr Graeme Kaufman, Mr Fullerton said "Graeme has both detailed biotech management experience and a global exposure to investors and industry contacts that make him ideally qualified to chair Bionomics, as the Company further internationalises its business, presence and shareholder base."

Mr Kaufman said "I welcome the opportunity to take a leadership role within Bionomics. The last three years under Chris Fullerton's stewardship has seen a transformation in the Company, building a solid base for the next exciting growth phase of our development. We thank Chris for his significant contributions and wish him all the best in his new ventures."

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.

BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210, a novel compound which stimulates neurite outgrowth. BNC210 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, and ET101, its licensing deal with Ironwood Pharmaceuticals, its acquisition of Eclipse Therapeutics, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement .